STOCK TITAN

Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Haemonetics Corporation (NYSE: HAE) releases financial results for Q1 fiscal 2024, available on its Investor Relations website. Conference call and webcast scheduled for investor discussion.
Positive
  • None.
Negative
  • None.

Financial release accessible online

BOSTON, Aug. 8, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal 2024, which ended July 1, 2023, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 8, 2023. The conference call and webcast can be accessed with the following information:

In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below.  

Direct link to 1Q FY24 Earnings Release:
https://haemonetics.gcs-web.com/static-files/59d8e57d-0800-42fb-9047-72f4fac27a89

A replay of the conference call and webcast will be available for one year beginning on August 8, 2023, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:                                                     


Olga Guyette, Sr. Director-Investor Relations & Treasury 

David Trenk, Manager-Investor Relations

(781) 356-9763                        

(203) 733-4987

olga.guyette@haemonetics.com              

david.trenk@haemonetics.com        



Media Contact:                                                                     


Josh Gitelson, Director-Global Communications


(781) 356-9776


josh.gitelson@haemonetics.com 


 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-1st-quarter-fiscal-year-2024-earnings-release-available-on-investor-relations-website-301895394.html

SOURCE Haemonetics Corporation

FAQ

What are the financial results released by Haemonetics Corporation for Q1 fiscal 2024?

Haemonetics Corporation has released its financial results for the first quarter of fiscal 2024, which ended on July 1, 2023.

Where can I access the financial results released by Haemonetics Corporation?

The financial results for Q1 fiscal 2024 released by Haemonetics Corporation are available on its Investor Relations website.

When is the conference call and webcast scheduled by Haemonetics Corporation?

Haemonetics Corporation will host a conference call and webcast with investors and analysts to discuss the financial results and answer questions.

Haemonetics Corporation

NYSE:HAE

HAE Rankings

HAE Latest News

HAE Stock Data

4.74B
50.37M
0.76%
101.04%
4.01%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
BOSTON

About HAE

haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right